SOD1 and amyotrophic lateral sclerosis: A phase I/II trial evaluating the safety effects of Qalsody in a cohort of 50 people with SOD1-ALS determined that Qalsody decreased SOD1 protein concentrations in cerebrospinal fluid (CSF) by up to 36% in the high-dose group and 3% in the low-dose group compared to placebo in a 12 weeks period.